CSIMarket
 


Abbott Laboratories  (ABT)
Other Ticker:  
 
 

ABT's Net Income Growth by Quarter and Year

Abbott Laboratories's Net Income results by quarter and year




ABT Net Income (in millions $) FY 2021 FY 2020 FY 2019 FY 2018
IV Quarter December - 2,162.00 1,049.00 654.00
III Quarter September - 1,232.00 960.00 563.00
II Quarter June - 537.00 1,006.00 733.00
I Quarter March 1,793.00 564.00 672.00 418.00
FY   1,793.00 4,495.00 3,687.00 2,368.00



ABT Net Income first quarter 2021 Y/Y Growth Comment
Abbott Laboratories achieved in the first quarter, above Company average Net Income surge of 217.91% year on year, to $ 1,793.00 millions.

Looking into first quarter results within Major Pharmaceutical Preparations industry 2 other companies have achieved higher Net Income growth. While Abbott Laboratories' s Net Income doubling of 217.91% ranks overall at the positon no. 277 in the first quarter.




ABT Net Income ( Y/Y Growth %) 2021
2020 2019 2018
IV Quarter December - 106.1 % 60.4 % -
III Quarter September - 28.33 % 70.52 % -6.63 %
II Quarter June - -46.62 % 37.24 % 159.01 %
I Quarter March 217.91 % -16.07 % 60.77 % -0.24 %
FY   - 21.91 % 55.7 % 396.44 %

Financial Statements
Abbott Laboratories's first quarter 2021 Net Income $ 1,793.00 millions ABT's Income Statement
Abbott Laboratories's first quarter 2020 Net Income $ 564.00 millions Quarterly ABT's Income Statement
New: More ABT's historic Net Income Growth >>


ABT Net Income (Quarter on Quarter Growth %)

2021
2020 2019 2018
IV Quarter December - 75.49 % 9.27 % 16.16 %
III Quarter September - 129.42 % -4.57 % -23.19 %
II Quarter June - -4.79 % 49.7 % 75.36 %
I Quarter March -17.07 % -46.23 % 2.75 % -
FY (Year on Year)   - 21.91 % 55.7 % 396.44 %




Net Income first quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #3
Healthcare Sector #16
Overall #277

Net Income Y/Y Growth Statistics
High Average Low
167.27 % 5.13 % -77.32 %
(Dec 31 2018)   (Dec 31 2017)
Net Income first quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #3
Healthcare Sector #16
Overall #277
Net Income Y/Y Growth Statistics
High Average Low
167.27 % 5.13 % -77.32 %
(Dec 31 2018)   (Dec 31 2017)

Net Income by Quarter for the Fiscal Years 2018, 2019, 2020, 2021

Abbott Laboratories's Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
434 % 16.95 % -84.39 %
(Dec 31 2011)  


ABT's I. Quarter Q/Q Net Income Comment
In the I. Quarter 2021 Abbott Laboratories disclosed fall in Net Income sequentially by -17.07% to $ 1,793.00 millions, from $ 2,162.00 millions achived a quarter before.

But that's not huge issue, as Abbott Laboratories's Net Income always tend to slow in this quarter Alicia Jansson, Healthcare sector researcher based in Stockholm noted.

Within Major Pharmaceutical Preparations industry 9 other companies have achieved higher Net Income quarter on quarter growth. While Abbott Laboratories's Net Income growth quarter on quarter, overall rank is 643.


Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #10
Healthcare Sector #40
Overall #643
Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #10
Healthcare Sector #40
Overall #643
Net Income Q/Q Growth Statistics
High Average Low
434 % 16.95 % -84.39 %
(Dec 31 2011)  


ABT's I. Quarter Q/Q Net Income Comment
In the I. Quarter 2021 Abbott Laboratories reported fall in Net Income from the forth quarter by -17.07% to $ 1,793.00 millions, from $ 2,162.00 millions achived in the previous reporting period.

It's not important issue, as Net Income always tend to slow in this quarter.

Within Major Pharmaceutical Preparations industry 9 other companies have achieved higher Net Income quarter on quarter growth. While Abbott Laboratories's Net Income growth quarter on quarter, overall rank is 643.


Abbott Laboratories's 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Mar 31 2021)
12 Months Ending
(Dec 31 2020)
12 Months Ending
(Sep 30 2020)
12 Months Ending
(Jun 30 2020)
12 Months Ending
(Mar 31 2020)
Cumulative Net Income 12 Months Ending $ 5,724.00 $ 4,495.00 $ 3,382.00 $ 3,110.00 $ 3,579.00
Y / Y Net Income Growth (TTM) 59.93 % 21.91 % 2.73 % 7.43 % 36.5 %
Year on Year Net Income Growth Overall Ranking # 241 # 479 # 834 # 679 # 330
Seqeuential Net Income Change (TTM) 27.34 % 32.91 % 8.75 % -13.1 % -2.93 %
Seq. Net Income Growth (TTM) Overall Ranking # 277 # 416 # 768 # 1374 # 1031




Cumulative Net Income growth Comment
Abbott Laboratories saw improvement in Net Income growth trend, posting cumulative 12 months Net Income growth of 59.93% year on year, to $ 5,724 millions if the fiscal year would have ended in Mar 31 2021.
Abbott Laboratories's trailing twelve months Net Income growth was higher than company's average 26.86% and higher than 21.91% growth in Dec 31 2020.
But from twelve months ended Dec 31 2020 growth rate was less at 27.34 % from $4495 millions achieved in the period from Dec 31 2020 to Mar 31 2020.
Yet this was evidence of convincing trend, as the typical Q/Q TTM Net Income growth is at 5.13%.
The growth was even stronger from the previous reporting period showed at 27.34 % jump from $4495 millions in the period from Dec 31 2020 to Mar 31 2020.

Within the Healthcare sector 21 other companies have achieved higher trailing twelve month Net Income growth. While Total ranking has impoved so far to 241, from total ranking in previous quarter at 479.

Net Income TTM Q/Q Growth Statistics
High Average Low
167.27 %
5.13 %
-77.32 %
 

Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 3
Healthcare Sector # 22
Overall # 241

Net Income TTM Y/Y Growth Statistics
High Average Low
450.84 %
26.86 %
-69.98 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 3
Sector # 16
S&P 500 # 277
Cumulative Net Income growth Comment
Abbott Laboratories saw improvement in Net Income growth trend, posting cumulative 12 months Net Income growth of 59.93% year on year, to $ 5,724 millions if the fiscal year would have ended in Mar 31 2021.
Abbott Laboratories's trailing twelve months Net Income growth was higher than company's average 26.86% and higher than 21.91% growth in Dec 31 2020.
But sequential growth rate was less at 27.34 % from $4495 millions recorded in twelve months ending a quarter before.
In spite of, this was evidence of positive momentum, as the average Q/Q TTM advancement is at 5.13%.
The momentum was even higher from twelve months ended Dec 31 2020 exhibited at 27.34 % rise from $4495 millions in the period from Dec 31 2020 to Mar 31 2020.

Within the Healthcare sector 21 other companies have achieved higher trailing twelve month Net Income growth. While Total ranking has impoved so far to 241, from total ranking in previous quarter at 479.

Net Income TTM Q/Q Growth Statistics
High Average Low
167.27 %
5.13 %
-77.32 %
 


Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 3
Healthcare Sector # 22
Overall # 241

Net Income TTM Y/Y Growth Statistics
High Average Low
450.84 %
26.86 %
-69.98 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 3
Sector # 16
S&P 500 # 277




Other Net Income Growth
Major Pharmaceutical Preparations Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
ABT's Net Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for ABT's Competitors
Net Income Growth for Abbott Laboratories's Suppliers
Net Income Growth for ABT's Customers

You may also want to know
ABT's Annual Growth Rates ABT's Profitability Ratios ABT's Asset Turnover Ratio ABT's Dividend Growth
ABT's Roe ABT's Valuation Ratios ABT's Financial Strength Ratios ABT's Dividend Payout Ratio
ABT's Roa ABT's Inventory Turnover Ratio ABT's Growth Rates ABT's Dividend Comparisons



Companies with similar Net Income fall for the quarter ending Mar 31 2021 within Healthcare SectorY/Y Change %Net Income for the quarter ending Mar 31 2021
Quest Diagnostics Inc362.26%$ 362.264 millions
Quidel Corporation342.59%$ 342.588 millions
Progyny Inc 273.82%$ 273.823 millions
U S Physical Therapy Inc256.08%$ 256.081 millions
Avantor Inc 248.94%$ 248.936 millions
Teva Pharmaceutical Industries Ltd236.00%$ 236.000 millions
Abbott Laboratories217.91%$ 217.908 millions
Repligen Corp200.05%$ 200.051 millions
Reynolds Consumer Products Inc 184.62%$ 184.615 millions
Meridian Bioscience Inc 181.03%$ 181.034 millions
Iqvia Holdings Inc 138.46%$ 138.462 millions
Hca Healthcare Inc 126.36%$ 126.361 millions


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

MUX's Profile

Stock Price

MUX's Financials

Business Description

Fundamentals

Charts & Quotes

MUX's News

Suppliers

MUX's Competitors

Customers & Markets

Economic Indicators

MUX's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071